DCprime is a privately owned, clinical stage biotechnology company focused on developing cell-based cancer vaccines. We are currently conducting a multi-centre Phase IIa trial for our lead product DCP-001 as a post-remission vaccine therapy in patients with Acute Myeloid Leukaemia (AML). DCprime aims to initiate additional clinical studies with DCP-001 in different haematological and solid tumours and continues to invest in preclinical cancer immunology research.